NCT05474417 The Effects of the CF Carrier State on the Kidneys and Pancreas
| NCT ID | NCT05474417 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Philip Polgreen |
| Condition | Carrier State |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,250 participants |
| Start Date | 2021-12-20 |
| Primary Completion | 2026-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,250 participants in total. It began in 2021-12-20 with a primary completion date of 2026-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The overarching hypothesis is that CF carriers are at increased risk for developing most of the extrapulmonary conditions associated with CF compared to the general population. Specifically, it is hypothesized that this pilot data will detect subclinical evidence of pancreatic and kidney disorders among CF carriers. This will be determined by bringing CF carriers and controls to the CRU for one visit where they will answer survey questions and undergo laboratory testing. Additionally, they will collect urine and stool samples at home that will be sent to outside laboratories for testing.
Eligibility Criteria
CF Carrier Inclusion Criteria: * A CF Carrier identified via genetic testing Control Inclusion Criteria: * No previous CF carrier test results Exclusion Criteria: * CF patient status * Unable to speak English * Currently pregnant * Unable to provide written informed consent * Prisoner status * Currently taking any medications for the treatment of diabetes
Contact & Investigator
Philip M Polgreen, MD
PRINCIPAL INVESTIGATOR
University of Iowa
Frequently Asked Questions
Who can join the NCT05474417 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Carrier State. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05474417 currently recruiting?
Yes, NCT05474417 is actively recruiting participants. Contact the research team at philip-polgreen@uiowa.edu for enrollment information.
Where is the NCT05474417 trial being conducted?
This trial is being conducted at Iowa City, United States.
Who is sponsoring the NCT05474417 clinical trial?
NCT05474417 is sponsored by Philip Polgreen. The principal investigator is Philip M Polgreen, MD at University of Iowa. The trial plans to enroll 1,250 participants.